Full-Time

Associate Director

Drug Safety Operations

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based gene-silencing therapies

Compensation Overview

$170k - $200k/yr

San Diego, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • 10 years of experience in Drug Safety/Pharmacovigilance Operations
  • Bachelor of Science/4-year degree in Biological or Life Sciences, pharmacy, nursing or related healthcare field.
  • Strong working knowledge of case management and processing. Experience in using ARGUS or other safety databases. Experience with MedDRA/WHO for coding AEs, medical history, and concomitant medications
  • Experience with preparation with aggregate reports, preferably for investigational drugs (i.e., DSURs, IND Annual reports) or post-marketing products (i.e., PSUR/PBRER, PADERs)
  • Working experience with Safety Databases (Argus, ArisG or other) is required.
  • Knowledge of ICH E2B guidelines in clinical and post-marketing studies.
  • Good organizational skills with the ability to perform multiple tasks efficiently and effectively
Responsibilities
  • Support Case Processing and support safety medical review, generate appropriate queries to contact drug safety vendors (CROs) to complete and clarify SAE case information as needed and work with CRO to determine when cases are complete and ready to close.
  • Partner with clinical and safety teams to support consistent, accurate, and regulatory‑compliant assessment and documentation of SAEs and events of special interest (e.g., pregnancy, overdose) across clinical programs.
  • Collaborate with cross‑functional stakeholders to support standardized safety set‑up for new clinical studies, including contribution to Safety Management Plans, Safety Monitoring Plans, Clinical Risk Management Plans, and safety system configurations.
  • Work closely with CROs and PV vendors to provide oversight of safety case management activities, including quality review processes and monitoring of expedited and aggregate reporting timelines.
  • Partner with Finance, Clinical Operations, and vendors to provide oversight of safety budgets and financial activities, including scope alignment, forecasting, invoice review, and cost tracking.
  • Collaborate with internal teams and external partners to manage Pharmacovigilance Agreements (PVAs), SDEAs, and vendor contracts, supporting compliance with regulatory, contractual, quality, and financial requirements.
  • Engage with safety vendors and CROs to monitor deliverables, support reconciliation processes, maintain TMF/eTMF safety documentation, and promote continuous improvement.
  • Coordinate with Clinical Operations, CROs, and PV vendors to support and oversee Clinical–Safety Database reconciliation activities, ensuring timely, accurate, and well‑documented reconciliation across studies.
  • Work in partnership with Safety Science and Medical teams to support safety surveillance activities, including signal detection, trend analysis, similar‑event evaluations, and review of abnormal laboratory data.
  • Collaborate with Regulatory Affairs and study teams to support safety reporting activities across clinical trials, including preparation for expedited reporting and health authority communications.
  • Partner with safety systems and vendor teams to support oversight of the Safety Database (e.g., Argus), including UAT, system updates, data outputs for DSURs, IBs, DSMB/DSC materials, and business continuity activities.
  • Support inspection readiness and regulatory inspection activities by collaborating on document preparation, reconciliation support, inspection responses, and participation in health authority inspections as needed.
  • Contribute to the authoring, review, and maintenance of SOPs, work instructions, and cross‑functional documents, while supporting team development and the Head of Clinical Safety & Pharmacovigilance in governance activities.
  • Support activities related to implementing and maintaining the Safety Database, supporting ARGUS activities, Overseeing the Safety Vendors, and coordinating the Safety Reporting from Clinical Trials and Collaborators.
  • Support other members of Safety Operations and Science personnel and ensure flawless execution of Safety and Pharmacovigilance processes
  • Participate in tracking/monitoring of cases and other vendor or partner deliverables to ensure quality and timeliness of safety management activities, as well as adherence to regulatory and contractual obligations.
  • Provide drug safety case management support to Safety medical monitors; assist in following up on queries for case reports, abnormal laboratory values, or any other relevant safety and medical data.
  • Support reviewing and monitoring of SAE/SUSAR case processing including, performing the secondary quality review for all case reports in the safety
  • Monitor SAE reconciliation with the Arrowhead PV vendor and study CRO to ensure the reconciliation process is occurring for all clinical studies
  • Support monitoring safety surveillance for Arrowhead's clinical development products to ensure corporate compliance with national and international adverse event reporting requirements
  • Participate in the production and validation of appropriate safety data output from the external or internal safety database for required safety deliverables (e.g. DSUR, IB, ad hoc analyses etc.).
  • Assist with periodic Disaster recovery and Business continuity tests as needed with Safety Database.
  • Support Drug Safety team with listings and data from the Argus database.
Desired Qualifications
  • HCP experience
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • REDEMPLO FDA approval drove $264M FQ1 2026 revenue and $30.8M profit from milestones.
  • $1B Madrigal deal for ARO-PNPLA3 provides $25M upfront plus milestones and royalties.
  • Breakthrough Therapy for plozasiran expands REDEMPLO to severe hypertriglyceridemia market.

What critics are saying

  • Madrigal out-licensing ARO-PNPLA3 eliminates internal MASH revenue by 2027.
  • Wave Life Sciences INHBE data erodes Arrowhead obesity program value in 2026.
  • Novartis and Sarepta withhold milestones if ARO-DIMER-PA fails Phase 1/2a in 2027.

What makes Arrowhead Pharmaceuticals unique

  • TRiM platform enables tissue-agnostic RNAi delivery across liver, pulmonary, and cardiometabolic diseases.
  • Pioneers dual-function siRNA like ARO-DIMER-PA targeting two genes in one molecule.
  • Targets undruggable genes via proprietary RNA chemistries for rapid, durable knockdown.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Arrowhead Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

Yahoo Finance
Mar 14th, 2026
Arrowhead swings to $30.8M profit on $264M revenue as FDA approves first drug REDEMPLO

Arrowhead Pharmaceuticals has raised $264 million in revenue for FQ1 2026, transitioning to a commercial-stage company following FDA approval of REDEMPLO (plozasiran), its first medicine for treating familial chylomicronemia syndrome. The drug also received regulatory clearance in China and Canada, with over 100 initial prescriptions in the US. The company swung to a net income of $30.8 million, compared to a $173.1 million loss in the prior year period. Revenue was boosted by a $200 million upfront payment from a collaboration with Novartis and a $200 million milestone from Sarepta Therapeutics. Arrowhead also initiated a Phase 1/2a trial for ARO-DIMER-PA, the industry's first dual-function clinical candidate targeting two genes in one molecule.

Access Market Intelligence
Feb 10th, 2026
Vanscoy Rare Pharmacy Selected as Exclusive Specialty Pharmacy Provider for Redemplo

Vanscoy Rare Pharmacy selected as exclusive specialty pharmacy provider for Redemplo. Vanscoy Rare Pharmacy, a leading specialty pharmacy focused on supporting people living with rare conditions, announced that it has been selected as the exclusive specialty pharmacy provider for Arrowhead Pharmaceuticals' Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis. With the FDA approval of Redemplo, patients will have access to a targeted treatment option designed to address the underlying cause of FCS. Through this agreement, Vanscoy Rare Pharmacy will provide patients with comprehensive support at each stage of their treatment journey with Redemplo. Arrowhead launched REDEMPLO independently in the U.S. with the OneREDEMPLO pricing model that creates one consistent price across current and potential future indications. Arrowhead is targeting approximately 5,000 healthcare professionals through personal promotion, complemented by a much broader omnichannel effort. REDEMPLO was recently approved by Health Canada's approval of REDEMPLO as a new treatment option for Canadians living with genetic or clinical FCS, giving patients, providers, and caregivers alike a convenient dosing option that can be self-administered at home with a subcutaneous injection once every three months. Pending regulatory review and approval, Arrowhead expects to potentially launch REDEMPLO later this year in select EU countries and in the UK. In Greater China, REDEMPLO will be marketed by Sanofi. #Redemplo #ArrowheadPharmaceuticals #FCS #VanscoyRarePharmacy #OneRedemplo #exclsuivespecialtypharmacy

Silence Therapeutics
Jan 22nd, 2026
Silence Therapeutics PLC - Acquisition of Minority Stake in Arrowhead

RNS Number : 6001T Silence Therapeutics PLC 09 January 2017 Acquisition of minority stake in Arrowhead Pharmaceuticals 9th January 2017 London, 9th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has acquired a stake, on-market, in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ("Arrowhead") of 6,006,359 common shares, representing 8.4% of the common share capital of Arrowhead, for a total cash consideration of $9.6 million (£7.8 million(1)), excluding transaction costs. Since the capital raise of May 2015, Silence has been actively evaluating a number of RNAi assets, including technologies within both listed and unlisted RNAi companies. Arrowhead is a US based NASDAQ listed company that develops medicines to treat intractable diseases by silencing the genes that cause them by means of a broad

Arrowhead Pharmaceuticals
Jan 22nd, 2026
Arrowhead Pharmaceuticals Closes $45 Million Private Offering - Arrowhead Pharmaceuticals, Inc.

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price […]

Investing.com
Jan 2nd, 2026
Bernstein raises Arrowhead Pharma stock price target to $35 on obesity data

Bernstein raises Arrowhead pharma stock price target to $35 on obesity data. Investing.com - Bernstein SocGen Group has raised the price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $35.00 from $17.00 while maintaining a Market Perform rating ahead of the company's upcoming obesity data update. The new target sits at the low end of analyst projections, which range from $35 to $100, according to InvestingPro data. Currently trading at $66.39, ARWR appears overvalued based on InvestingPro's Fair Value assessment. The price target adjustment reflects increases to Bernstein's severe hypertriglyceridemia (SHTG) estimates and the addition of obesity treatment potential to their valuation model. The new target represents the average of a discounted cash flow analysis to 2035 and an enterprise value to revenue multiple of 1.75x 2035 revenue. This valuation approach aligns with ARWR's current high multiples, with InvestingPro data showing an EV/EBITDA of 72.58 and a Price/Book ratio of 19.36. Bernstein noted that Arrowhead is among several companies pursuing non-incretin mechanisms to treat obesity, with the aim of reducing fat while preserving muscle. Other companies in this space include Eli Lilly, Roche, Regeneron, Scholar Rock, Wave Life Sciences, Alnylam, and Biohaven. Despite not being profitable over the last twelve months, ARWR maintains a strong financial health score of "GREAT" according to InvestingPro's comprehensive analysis, with liquid assets exceeding short-term obligations. The analyst highlighted recent data from Wave Life Sciences suggesting that INHBE, which Arrowhead is also pursuing, may be a better target than myostatin. This disclosure on December 8 generated substantial investor excitement, with Wave shares rising 150% and Arrowhead gaining 12%. Despite the price target increase, Bernstein recommends staying on the sidelines for Arrowhead's upcoming data update, suggesting approximately 20% potential movement in either direction. The firm believes shares are already pricing in substantial optimism, estimating $10-15 of obesity treatment value in the current stock price. In other recent news, Arrowhead Pharmaceuticals has launched Redemplo for Familial Chylomicronemia Syndrome, with Piper Sandler forecasting significant U.S. sales by 2026. The firm raised its price target for Arrowhead to $100, noting Redemplo's superior attributes compared to other treatments. RBC Capital also increased its price target for Arrowhead to $80, citing positive developments and early commercial traction for Redemplo, as well as optimism about upcoming trial results for the company's severe hypertriglyceridemia candidate. H.C. Wainwright set its price target at $85, praising the recently approved Redemplo label for its safety and convenience. Additionally, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Arrowhead's investigational drug plozasiran for severe hypertriglyceridemia. Arrowhead has also dosed the first subjects in a Phase 1/2a clinical trial for ARO-MAPT, targeting tauopathies such as Alzheimer's disease. This trial utilizes a new delivery system designed to cross the blood-brain barrier, showing potential in preclinical studies. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you be buying ARWR right now? ProPicks AI evaluates ARWR alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ARWR is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?